






EFFECT OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) ON HIV-1 
TAT PROTEIN-INDUCED NEUROTOXICITY 
By 
Simo Siyanda Zulu  
(207506590) 
B Sc., B. Medical Sciences Honours (UKZN) 
 
Submitted in partial fulfillment of the requirements for the degree of Master of Medical 
Sciences in the School of Laboratory Medicine and Medical Sciences, in the Collage of 














I would like to express gratitude to the following people, without whom this work would not have been 
successful. 
To my supervisors Professor W.M.U. Daniels and Dr. M.V. Mabandla, you have both gave me support, 
motivation. Your guidance helped me in all the times of research. 
My sincere thanks also go to all my colleagues from Neuroscience group, for the stimulating discussions, 
and for all the fun we have had in the last years. 
My special and heartily thanks to Professor V.A. Russell and M. Morelli for their contribution, their 
information helped me complete this dissertation. 
I thank and appreciate the financial support from the Collage of Health Sciences. 
I also thank my family who encouraged me and prayed for me throughout the time of my research. This 
thesis is heartily dedicated to my mother for the unfailing love you showed me. 







Table of contents 
No.    Contents          Pages 
 Study Title i 
 Declarations ii 
 Acknowledgments iii 
 Table of content iv-v 
 List of figures and tables vi-vii 
 Abbreviations viii-ix 
 Abstract x-xi 
 Chapter 1  
1 Literature review 1 
1.1 Introduction  1-2 
1.2 HIV-TAT PROTEIN   
1.2.1 HIV Tat protein (Tat) - structure and function   3-4 
1.2.2 Mechanisms of Tat-induced neuronal damage    5-7 
1.2.3 Neuro-inflammation and HAND 7-8 
1.3 ANTIRETROVIRAL THERAPY and HIV   
1.3.1 Antiretroviral drugs mechanism  9-11 
1.3.2 Adverse effects of antiretroviral therapy (ART) 11-13 
1.3.3 Antiretroviral drugs and blood-brain-barrier permeability 13-14 
1.4 BRAIN AREAS  




1.5 Aims of the study 16 
1.6 Hypothesis 16 
1.7 Objectives 16 
2 Chapter 2 (Research paper) 17-40 
3 Chapter 3 (Conclusions and Future considerations) 41-42 


























List of figures and tables 
           
Chapter 1 Legends Pages 
Figure 1 Showing the mechanism of HIV entry into the central nervous system 2 
Figure 2 
 





Schematic illustration of astrocyte activation and excitoxicity induce by HIV Tat protein 
 
4 
Figure 4 Showing action site of antiretroviral drugs in cell 8 
Figure 5 Showing the brain areas forming part of the limbic system 10 
 
Chapter 2                   Legends Pages 
Figure 1 Active caspase-3 levels in hippocampal tissue of rats that received bilateral intrahippocampal 
injections of Tat or saline, followed by treatment with HAART or saline for 7 days, 14 days 
after Tat injection. a The western blot representation of cleaved caspase-3 and β-actin. b Graph 
representing the cleaved caspase-3 measurements after normalization against β-actin. 
*Significantly different from Saline+Saline group. # Significantly different from the 





HNE levels in hippocampal tissue of rats that received bilateral intrahippocampal injections of 
Tat or saline, followed by treatment with HAART or saline for 7 days, 14 days after Tat 








TNF-α levels in hippocampal tissue of rats that received bilateral intrahippocampal injections of 
Tat or saline, followed by treatment with HAART or saline for 7 days, 14 days after Tat 
injection. *Significantly different from Saline+Saline group, # significantly different from 





Phosphorylated ERK 1/2 levels in hippocampal tissue of rats that received bilateral 
intrahippocampal injections of Tat or saline, followed by treatment with HAART or saline for 7 
days, 14 days after Tat injection. a Western blot representation of pERK. b Graph showing 
pERK measurements after normalization against β-actin. *Significantly different from 





Synaptophysin levels in hippocampal tissue of rats that received bilateral intrahippocampal 
injections of Tat or saline, followed by treatment with HAART or saline for 7 days, 14days 
after Tat injection. a Western blot representation of synaptophysin. b Graph showing 
























4-HNE  4-Hydroxynonenal 
ADP  Adenosine Diphosphate 
AIDS   Acquired Immunodeficiency Syndrome 
AP Anterior-Posterior 
ARV Antiretroviral 
ART Antiretroviral therapy 
CD 4  Cluster of Differentiation 4 
DNA  Deoxyribonucleic Acid 
DV Dorsal-Ventral 
ELISA Enzyme Linked Immunosorbent Assay 
Fig.  Figure  
g Gram 
HAART Highly Active Antiretroviral Therapy 
HAND  HIV-Associated Neurocognitive Disorder 
HIV Human Immunodeficiency Virus 
kg Kilogram 
MAPK Mitogen-Activated Protein Kinases 
mg  Milligram 
ML Medial-Lateral 
mm Millimeter 
NF-Ƙβ  Nuclear Factor kappa-beta 
o










Reactive Oxygen Species 
Tat Trans-activating 
























Background: HIV-1-trans-activating (Tat) protein has been associated with development of HIV-
associated neurocognitive disorder (HAND). Previous studies have demonstrated that Tat protein causes 
neurotoxicity through an increase in reactive oxygen species (ROS) leading to damage of proteins and 
other cellular components. Tat has also been shown to cause excessive production of pro-inflammatory 
cytokines. However the role of antiretroviral agents in the neuropathology of HIV is not known. The 
objective of this study was to investigate whether a combination of antiretroviral drugs (Zidovudine, 
Lamivudine and Efavirenz, a highly active antiretroviral therapy, HAART) is effective in reducing the 
toxic effects of Tat protein in the rat hippocampus. 
Materials and methods: Male Sprague-Dawley rats were divided into four groups (n=10 per group). Each 
rat received bilateral intrahippocampal injection of either Tat protein (5µg/10µL) or vehicle, followed 7 
days later by a combination of antiretroviral drugs (Zidovudine 12mg/kg, Lamivudine 6mg/kg and 
Efavirenz 24mg/kg) or saline injected intraperitoneally, twice a day, for 7 days. After treatment, animals 
were sacrificed and hippocampal tissue was collected for analysis of cleaved caspase-3, 4-
hydroxynonenal (NHE), tumor necrosis factor alpha (TNF-α), phosphorylated extracellular signal-
regulated kinase (pERK) and Synaptophysin. 
Results: Tat increased cleaved caspase-3 levels in the hippocampus. Antiretroviral treatment decreased 
the Tat-induced increase in cleaved caspase-3. Tat increased HNE, a marker of lipid peroxidation and 
reduced hippocampal synaptophysin. The latter Tat-induced effects were not reversed by antiretroviral 
treatment. The antiretroviral drug combination activated the pERK pathway and increased TNF-α levels 
in hippocampal tissue, independent of Tat infusion. 
Discussion: Our findings showed that antiretroviral drugs reversed Tat-induced cleaved caspase-3, 
reducing apoptosis but did not reverse Tat-induced increase in lipid peroxidation and the synaptic marker, 




hippocampal pERK and TNF-α levels. However, these effects could also be beneficial to the individual, 
since TNF-α has been shown to inhibit viral replication. The present results provide novel insight into the 
mechanism of antiretroviral action.  
























 1. Literature Review  
1.1 Introduction 
Neurological complications have become a major concern in people living with HIV and AIDS 
(Joska et al., 2011). These complications may range from deficits in motor function (loss of 
balance, motor activity slowness) to difficulties in learning, and memory loss (Nakku et al., 
2013). These motor and cognitive impairments (mental slowing, attention/memory deficits) are 
collectively referred to as HIV-associated neurocognitive disorder (HAND) (Brew and Perdices, 
1992). HAND has been classified into three forms i.e. HIV-associated asymptomatic 
neurocognitive impairments (ANI), HIV-associated mild neurocognitive disorder (MND) and 
HIV-associated dementia, also known as AIDS dementia complex (Brew and Perdices, 1992, 
Manji et al., 2013).  
HIV enters the brain soon after infection and remains in the brain throughout the course of the 
disease regardless of immune response (An et al., 1999). HIV entry into the central nervous 
system (CNS) may occur in two ways, (i) direct uptake through the blood-brain-barrier (BBB) 
and (ii) through infected immune cells (macrophages and T-lymphocytes) which are considered 
to be the primary vehicles for HIV entry into the CNS. The presence of HIV in the CNS can 
subsequently lead to recruitment of additional immune cells which results in further disruption of 




Figure1: showing the mechanism of HIV entry into the central nervous system (Ivey et al., 2009). 
 
Infected monocytes and lymphocytes have the ability to release cellular and viral toxins into the 
extracellular space within the CNS (Dou et al., 2004). These toxins travel through anatomical 
pathways to subcortical areas such as the hippocampus and basal ganglia. Damage to these areas 
has been proposed to be responsible for the decline in cognitive function  as seen in HAND 
(McArthur et al., 2010). Viral proteins such as glycoprotein 120 (gp120) and transactivator of 
transcription (Tat) protein, have been shown to promote the secretion of proinflammatory 
cytokines/chemokines that may cause neuropathogenesis (Lee et al., 2011). It has further been 
shown in mice that Tat itself may lead to neuronal damage which results in abnormalities in 






1.2 HIV-TAT PROTEIN 
1.2.1 HIV Tat protein (Tat) - structure and function 
HIV Tat protein (Tat) is a transactivator protein that contributes to transactivation of viral and 
cellular genes (Ensoli et al., 1993, Song et al., 2007). Tat protein binds to the Trans-activation 
response element (TAR) of long terminal repeats and promotes expression of viral genes 
(Dingwall et al., 1990). It is a small protein of 86-104 amino acids encoded by two exons and its 
size varies between 14-16 kDa (Ruben et al., 1989).  
 
Figure 2: Showing site which HIV Tat protein act to activate transcription (Zhou and Yik, 2006) 
Tat is the first protein synthesized during HIV replication. When proviral DNA gets incorporated 
into the host cell genome, Tat synthesis is initiated (Romani et al., 2010).  Once Tat is produced, 
it is often found within the nucleus and nucleolus (Ponti et al., 2008). It therefore has the 
potential to bind to different TAR in RNA (Dingwall et al., 1990). Tat drives viral replication 
through transactivation of the promoter region called long terminal repeat (LTR) of the virus (Li 
et al., 2009). The first exon of Tat is involved in transcription activation and the second exon 
mediates Tat binding to cellular surface intergrins (Shojania et al., 2010). Tat attracts host 
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positive transcription elongation factor b (p-TEFb) to the RNA hairpin formed at the 5’-end of 
the viral RNAs (TAR) (Feng and Holland, 1988). P-TEFb is a complex formed by two subunits 
called cdk9 and cyclin T1. The subunits control the RNA polymerase during transcription (Price, 
2000). Tat recruits p-TEFb which then phosphorylate the C-terminal domain (CTD) repeats of 
RNA polymerase II (Jones and Peterlin, 1994). 
It is known that HIV-1 Tat induces several inflammatory cytokines. However in vitro studies 
showed that recombinant HIV-1B Tat induces monocytes to secrete proinflammatory cytokines 
greater than HIV-1C Tat (Gandhi et al., 2009, Wong et al., 2010). A study performed on human 
primary neurons showed that HIV-1C Tat is relatively less neurotoxic compared to HIV-1B Tat. 
This was linked to variations in the dicysteine motif of both clades  (Mishra et al., 2008). 
 Both in vivo and in vitro studies have demonstrated Tat to have neurotoxic effects (Agrawal et 
al., 2012, Capone et al., 2013). The actual half-life of Tat protein in the brain and peripheral 
circulation has not been well studied. Since factors such as proteases and those that regulate 
protein up-take control the half-life. However a study by Desfosses et al. (2005)has shown that 
the half-life of Tat was approximately 3 hours in HEK 293 cells. Notwithstanding uncertainty as 
to the half-life of tat, a study by Bansal et al. (2000) showed that 5µg/µl of Tat injected into the 
striatum caused a significant tissue loss and an increase in GFAP expression in astrocytes at the 
site of injection 7 days after injection. The deleterious effects of Tat were therefore evident 1 
week after administration and hence suggested that tat may elicit long term damaging 






1.2.2 Mechanisms of Tat-induced neuronal damage 
HIV-infected cells release Tat into the extracellular fluid of the brain. From here Tat is able to 
enter non-infected target cells and induce its toxic effects intracellularly (Romani et al., 2010). 
After Tat is internalized it causes neurodegeneration through various ways that include oxidative 
stress and excitotoxic processes brought about by activation of glutamate receptors.   
  
Figure 3: Schematic illustration of astrocyte activation and excitoxicity induce by HIV Tat protein (Ton 
and Xiong, 2013).   
Tat has been shown to activate NADPH oxidase in microglial cells causing high glutamate 
release via the xc cysteine-glutamate antiporter (Gupta et al., 2010). To protect itself from 
intracellular ROS accumulation, microglia cells take up cysteine for glutathione synthesis in 
exchange for glutamate (Piani and Fontana, 1994). Glutamate that is released into the 
extracellular space/synaptic cleft is then cleared by astrocytes through excitatory amino acid 
transporters (Bergles and Jahr, 1997). However excess glutamate in the synaptic cleft, can 
activate NMDA and non-NMDA receptors resulting in the opening of channels and subsequent 
influx of ions such as sodium and calcium into the cytoplasm (Bonavia et al., 2001). High 
6 
 
intracellular sodium levels often lead to necrotic death due to the hypertonic swelling of cells 
(Churchwell et al., 1996), while increased calcium influx may trigger the release of calcium ion 
from intracellular stores (e.g. endoplasm reticulum) to further flood the intracellular space with 
free calcium ions (Schinder et al., 1996). In response to protect the cells, mitochondria will take 
up large amounts of calcium through its electrochemical gradient, but this may lead to the 
disruption of the electrical potential across the mitochondria membrane (Schinder et al., 1996). 
Accumulation of calcium ions in the mitochondria may also cause osmotic swelling leading to 
the rapture of the outer membrane resulting in the release of the enzyme cytochrome c 
(Brustovetsky et al., 2002). Cytochrome c, procaspase 9 and apoptosis activating factor 9 
(Apaf1) form a multi-protein complex apoptosome that activates caspase 9 (Garden et al., 2002). 
Activated caspase 9 cleaves procaspase 3 to produce cleaved caspase 3, one of the apoptosis 
executioner enzymes (Tenneti et al., 1998, Garden et al., 2002). Tat therefore may either cause 
necrotic or apoptotic cell death. 
Neuro-inflammatory cells like microglia/macrophages, when activated, release 
chemokines/cytokines and reactive oxygen species (Gupta et al., 2010) and accumulation of 
these agents may lead to neuronal dysfunction (Kim et al., 2008, Capone et al., 2013). Cytokines 
such as tumor necrosis factor-α (TNF-α) and interleukin-1β released by infected 
macrophages/microglia can stimulate astrocytes to release of ROS (Buscemi et al., 2007, Sheng 
et al., 2013). Tat can also directly activate nitric oxide synthase (NOS) (Liu et al., 2002) to 
produce nitric oxide (NO), which is a nitrogen free radical (Stewart et al., 2000). In addition 
superoxide is released by HIV-infected macrophages and astrocytes (Sheng et al., 2013). The 
neurotoxicity of NO and superoxide is enhanced when they react with each other to form 
peroxynitrite, a potent oxidant that by damaging neurofilaments disrupts the structural stability 
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of the cell, leading to cellular dysfunction (Stewart et al., 2000).  (Aksenov et al., 2001) 
demonstrated that a single injection of 5-50 µg/µl of recombinant Tat (1-72 amino acids) into the 
striatum of Sprague–Dawley male rats, caused tissue loss surrounding injection in a dose 
dependent manner. On the other hand it has been shown that HIV-1 clade B Tat induced 
increasing expression of CD11b, a phagocytosis receptor molecule in microglia that was 
associated with an increase in lipid peroxidation.  Recently HIV-1 clade B Tat was reported to 
cause increase of spermine oxidase, an enzyme involved in the formation of hydrogen 
peroxidase, glutathione disulfide and a decline in glutathione (Capone et al., 2013).  
In summary it appears that HIV-associated cellular damage may be caused by viral proteins such 
as Tat through mechanisms that may involve heightened glutamate release, influx of cations, the 
generation of ROS and the activation of necrotic and apoptotic pathways. 
1.2.3 Neuro-inflammation and HAND 
Soon after infection HIV-1 gain access to the central nervous system by passing through the 
blood-brain-barrier (BBB) via infected monocyte and lymphocytes (Gras and Kaul, 2010). Since 
infected monocyte/macrophages and lymphocyte actively support HIV-1 replication, these cells 
can release virions into the extracellular space (Fanales-Belasio et al., 2010). In the brain HIV-1 
then infects neuroglia cells such as microglia and astrocytes. The entry of HIV-1 in microglia is 
mediated by CD4 receptors, whereas in astrocytes HIV-1 may enter via the chemokine co-
receptor CCR5 (Liu et al., 2004). Microglial cells also support HIV-1 replication, further 
spreading the infection within the brain (Bagasra et al., 1996). Although astrocytes can get 
infected, they do not support HIV-1 replication (Gray et al., 2014). Astrocytes block HIV-1 
replication by inhibiting the expression of HIV-1 regulatory proteins, Nef, Rev and Tat (Sabri et 
8 
 
al., 2003). Infected microglia and astrocytes are activated to release pro-inflammatory cytokines 
such as TNF-α and Interleukin-1β (Walsh et. al., 2014), glutamate (Bezzi et al., 2001, Huang et 
al., 2011).  
The pro-inflammatory cytokines such as TNF-α and interleukin-1β have been proposed to 
contribute to the death of neurons observed in HAND (Kaul et al., 2001). It has been 
demonstrated that TNF-α can disrupt the integrity of the BBB and increase its permeability 
(Fiala et al., 1997) by activating the expression of transmigration molecules such as intercellular 
adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) on the cell 
surface of endothelial cells of the BBB (Brabers and Nottet, 2006), therefore TNF-α plays an 
important role in HIV-1 infection of the brain. In addition to BBB disruption and increased 
ICAM-1 and VCAM-1 expression, TNF-α also up-regulates the production and release of 
monocyte chemoattractant protein-1 (MCP-1) (Hurwitz et al., 1995). This chemokine serves to 
attract monocytes and macrophages towards the site of infection.  
Studies have now showed that TNF-α causes excitoxicity by influencing the glutamatergic 
system in the brain. TNF-α mediates neurotoxicity by over stimulating glutamate receptors such 
as NMDA receptors, leading to excessive calcium influx, dysregulation of mitochondrial 
function, generation of reactive oxygen species, and eventual neuron damage (Bezzi et al., 2001). 
A second mechanism by which TNF-α affects the glutamatergic system, is by inhibiting the up-
take of this neurotransmitter by astrocytes, and thereby enhancing the synaptic concentration of 
glutamate resulting in excitoxicity (Fine et al., 1996). Thirdly TNF-α, together with interleukin-
1β co-operate to induce cytokine-inducible nitric oxide synthase (iNOS) (Jana et al., 2005). 
Activation of this enzyme produces nitric oxide leading to the development of oxidative stress 
and subsequent cell death (Chao et al., 1996).   
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1.3 ANTIRETROVIRAL THERAPY  
1.3.1 Antiretroviral drugs mechanism 
Since HIV mainly attacks the cells of the immune system, the primary function of antiretroviral 
(ARV) therapy has been to decrease the viral load. In general the approach is to inhibit the 
replication of the virus and in doing so, functioning of the immune system can be restored. In 
practice patients with HIV/AIDS are routinely treated with a combination of antiretroviral drugs 
that includes entry inhibitors (EI), nucleoside analogue reverse transcriptase inhibitors (NRTIs), 
non-nucleoside reverse transcriptase inhibitors (NNRTIs), integrase inhibitors and protease 
inhibitor (PIs). The combinational approach is considered most effective for the treatment of 
HIV/AIDS since it is able to inhibit viral replication at various stages of the HIV life cycle 
(Thein et al., 2014). This approach is commonly referred to as highly active antiretroviral 
therapy (HAART).  
Entry inhibitors are antiretroviral agents that prevent attachment of HIV to the target cell surface. 
Entry inhibition occurs in two ways, first through agents that binds to the gp41 envelope of the 
HIV membrane preventing fusion of the HIV membrane with the cellular membrane (Margolis et 
al., 2013). The second mechanism involves chemokine co-receptor 5 (CCR5) antagonists. CCR5 
is a receptor found on most immune cells such as macrophages and T-cells. Binding of HIV to 
CCR5 has been shown to be important for HIV entry into the cell (Davies and Taylor, 2013).  
Non-nucleoside and nucleoside/nucleotide reverse transcriptase inhibitors suppress HIV 
replication through blocking the production of double stranded DNA from virus RNA (Arts and 
Hazuda, 2012). NRTIs  (Zidovudine and Lamivudine) terminate the addition of nucleotides to 
the DNA strand (Jochmans, 2008).  NRTIs are deoxyribonucleosides that lack the 3’-OH group. 
They therefore block the addition of deoxyribose sugars into the newly formed DNA strand, 
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resulting in termination of viral DNA synthesis (Isel et al., 2001). Antiviral activity of NRTIs is 
dependent on cell metabolism. Host cell kinase enzymes phosphorylate NRTIs to NRTI-
triphosphates and it is in this form that they bind to the newly synthesized DNA strand to prevent 
subsequent elongation (Balzarini et al., 2002).    
 NNRTIs (Efavirenz) are structurally different from NRTIs and do not require phosphorylation to 
perform their antiviral activity (Balzarini et al., 1998). Binding of NNRTIs to reverse 
transcriptase causes a conformational change in the substrate binding site, while simultaneously 
reducing the activity of the DNA polymerase enzyme (Arts and Hazuda, 2012). These two 
effects facilitate the inhibition of viral DNA production. HIV integrase is an essential enzyme for 
viral replication following reverse transcription of viral RNA into double-stranded DNA. HIV 
integrase processes the insertion of HIV proviral DNA into the cellular genome of the host 
(Summa et al., 2008). Integrase inhibitors therefore prevent the transfer of viral DNA strands 
into the nucleus and block the incorporation of the viral DNA strands into the host cellular 
genome (Mazumder et al., 1997, Davies and Taylor, 2013).  
Protease inhibitors bind to the active site of the HIV protease enzyme preventing the action of 
proteases. Protease activity is important for the cleaving of viral proteins during virion 




Figure 4:  Showing action site of antiretroviral drugs in cell (Smith et al., 2013) 
 
 
1.3.2 Adverse effects of antiretroviral therapy (ART) 
Since antiretroviral therapy to people living with HIV/AIDS is a life-long treatment, many 
studies have been conducted to evaluate effects of these drugs on the normal structure and 
function of various organs of the body. These investigations have been proven to be important as 
they indicated possible reasons for the poor treatment adherence of many patients to ART 
(Monforte et al., 2000). Initially systemic disorders such as diabetes and lipid dystrophy have 
been noted. (Rosenkranz et al., 2007). It shown that chronic treatment of murine adipocytes with 
some PIs and NRTIs decrease adipocyte lipid metabolism and increase secretion of 
proinflammatory cytokines (Lagathu et al., 2004, Vernochet et al., 2005). However in addition to 
these metabolic disorders, liver damage has also been reported as a common adverse effect 
(Rosenkranz et al., 2007). Subsequently it has been shown that the kidneys are also negatively 
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affected by ART with both tubulopathy (Labarga et al., 2009) and nephropathy (Kalyesubula and 
Perazella, 2011) been observed in patients with HIV/AIDS that are on ART. 
These adverse effects have mainly been seen in patients on NNRTIs, NRTIs and PIs (Monforte 
et al., 2000, Rosenkranz et al., 2007) and have been suggested to result from mitochondrial 
impairment (Dalakas, 2001, Gerschenson and Brinkman, 2004). Evidence associating NRTIs and 
NNRTIs with mitochondrial malfunction has been convincing with a possible mechanism of 
action been proposed. ARVs selectively inhibit mitochondrial DNA polymerase gamma leading 
to a depletion of mitochondrial DNA (Lim and Copeland, 2001). This depletion of mitochondrial 
DNA results in reduction of mitochondrial enzymes necessary for oxidative phosphorylation 
(Gegg et al., 2009). Disruption of oxidative phosphorylation may lead to the leakage of electrons 
(Beyer, 1992), promoting the generation of  ROS. The subsequent formation of ROS then cause 
oxidative damage resulting in a decrease in ATP production. (Gegg et al., 2009). Studies 
conducted in human primate and rodents have shown that conditions such as lip dystrophy and 
insulin resistance may results after prolong exposure to NRTIs and NNRTIs  (Waters and 
Nelson, 2007). Although the toxicity of ARVs has been studied in several organs, the toxic effect 
of ARVs on the brain and their role in HAND remains poorly understood. 
The standard therapeutics used for HIV management consists of two NRTIs and NNRI or PI 
(Hammer et al., 2008).  Since these drugs are taken over long periods of time, interest has been 
raised to its effects on the central nervous system (CNS) (Husstedt et al., 2002), as such HIV-
infected patients on ART showed a complete suppression of HIV replication, but simultaneously 
exhibited characteristics of cognitive malfunction (Giunta et al., 2011). Drug-related CNS 
toxicity has subsequently become a cause of concern for many researchers especially in 
conditions such as HIV/AIDS where viral-induced brain abnormalities are also expected (Carr 
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and Cooper, 2000). This concern has been highlighted by recent reports showing ARTs affecting 
brain function (Liner et al., 2010) and observations of patients who discontinue ART to display 
an improvement in cognitive function (Robertson et al., 2010).  However reports such as these 
are not only limited at present, they also do not reveal a mechanism of action as to how ART 
mediates its effects on the CNS. Interestingly some clinicians prefer the use of drugs with a high 
BBB penetration rate in order to prevent the brain from becoming a HIV reservoir (Marra et al., 
2009, Tozzi et al., 2009). It is therefore obvious that the impact of ART on the brain is 
controversial and more studies are required to improve our current knowledge in this area of 
HIV/AIDS research.  
1.3.3 Antiretroviral drugs and blood-brain-barrier permeability  
The blood-brain-barrier (BBB) is a selective permeable barrier that separates the circulating 
blood from the extracellular fluid in the central nervous systems. BBB is found along all central 
nervous system capillaries and consists of endothelial cells which are connected by tight 
junctions (Abbott et al., 2010). The access of the brain by various molecules is dependent on 
their ability to penetrate the BBB. The penetration of drugs including antiretroviral drugs across 
BBB is linked to several factors. These include physical and chemical characteristics of both 
drugs and the BBB such as the molecular weight of the drug, whether the drug is bound to 
plasma proteins, the degree of ionization and lipid solubility of molecules and the presence of 
molecular pumps within the BBB (Mangas-Sanjuan et al., 2010). 
The link between antiretroviral drugs, BBB penetration and HAND has been reported by many 
authors (Caniglia et al., 2014) has recently reported that initiation of a combined antiretroviral 
therapy regimen with a high CNS Penetration Effectiveness score increases the risk of HIV 
14 
 
dementia. A study conducted in South Africa showed that there was no significant difference in 
cognitive outcomes between higher and lower CPE regimen groups (Cross et al., 2013). In 
addition to drug regimens comparing, researchers have investigated the CPE of individual drugs 
from all classes of antiretroviral drugs.   
In the NRTIs class, Zidovudine has been shown to possess a high penetration rate followed by 
Stavudine, Didanosine and Lamivudine (Strazielle and Ghersi-Egea, 2005). The high CPE is 
associated with its lipid solubility and less plasma protein binding (Burger et al., 1993). 
Nevirapine has a good CPE among NNRTIs followed by Efavirenz (Antinori et al., 2005). 
Poorer CPE observed with Efavirenz is associated with it molecular weight and also high plasma 
protein binding affinity (Ene et al., 2011). Most PIs are substrates of P-glycoprotein-1, a cell 
membrane protein that pumps many foreign substances out of cells (Kim et al., 1998, Choo et al., 
2000). Plasma protein binding has been shown to be high among PIs. These are linked to PIs 
having a poor CPE and their low cerebrospinal fluid concentration (Kageyama et al., 1994).  
1.4 BRAIN AREAS 
1.4.1 Hippocampus and the HIV 
Clinical studies have shown that the limbic system is important for normal cognitive function 
(Shaw and Alvord, 1997) Brain regions that make up the limbic system include thalamus, 




Figure 5: Showing the brain areas forming part of the limbic system (Sokolowski and Corbin, 2012) 
 
Of these the role of the hippocampus in learning and memory has extensively been studied 
(Alvarez et al., 1995, Assunção et al., 2007).  
Implanting Tat-producing cells into the striatum or dentate gyrus of rats, Bruce-Keller and 
colleagues (2003) could demonstrate how this protein is transported through anatomical 
pathways to various areas in the brain where it caused neurotoxic damage. It is therefore 
conceivable that HIV may enter the brain, where it produces and releases tat that is able to locate 
to brain regions involved in cognition. Support for this notion comes from studies where 
difficulties in learning, memory and poor attention had been observed in patients with HIV (Nakku et 
al., 2013). In addition a study conducted by Fitting et al. (2008) showed rats pups that received 






1.5 Aims of the study 
In view of the uncertainties in the current literature, the following aims were formulated for the 
present study: 
Aim 1: - to confirm the neurotoxic properties of Tat, 
Aim 2: - to investigate whether ART may be toxic, and  
Aim 3: - to investigate whether ART may block the neurotoxic effects of Tat 
1.6 Hypothesis:  
We hypothesized that antiretroviral therapy (ART) will not display any toxic effects and that the 
administration of ART will protect the brain against Tat-induced neurotoxicity.  
1.7 Objectives: 
The objectives of our study were: 
1. To inject Tat into the hippocampus of rats and assess the effects thereof on specific 
molecular markers of oxidative stress and apoptosis, 
2. To determine in which way ART may affect these molecular markers, and  
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Background: HIV-1-trans-activating (Tat) protein has been associated with development of 
HIV-associated neurocognitive disorder (HAND). Previous studies have demonstrated that Tat 
protein causes neurotoxicity through an increase in reactive oxygen species (ROS) leading to 
damage of proteins and other cellular components. Tat has also been shown to cause excessive 
production of pro-inflammatory cytokines. However the role of antiretroviral agents in the 
neuropathology of HIV is not known. The objective of this study was to investigate whether a 
combination of antiretroviral drugs (Zidovudine, Lamivudine and Efavirenz, a highly active 
antiretroviral therapy, HAART) is effective in reducing the toxic effects of Tat protein in the rat 
hippocampus. 
Materials and methods: Male Sprague-Dawley rats were divided into four groups (n=10 per 
group). Each rat received bilateral intrahippocampal injection of either Tat protein (5µg/10µL) or 
vehicle, followed 7 days later by a combination of antiretroviral drugs (Zidovudine 12mg/kg, 
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Lamivudine 6mg/kg and Efavirenz 24mg/kg) or saline injected intraperitoneally, twice a day, for 
7 days. After treatment, animals were sacrificed and hippocampal tissue was collected for 
analysis of cleaved caspase-3, 4-hydroxynonenal (NHE), tumor necrosis factor alpha (TNF-α), 
phosphorylated extracellular signal-regulated kinase (pERK) and Synaptophysin. 
Results: Tat increased cleaved caspase-3 levels in the hippocampus. Antiretroviral treatment 
decreased the Tat-induced increase in cleaved caspase-3. Tat increased HNE, a marker of lipid 
peroxidation and reduced hippocampal synaptophysin. The latter Tat-induced effects were not 
reversed by antiretroviral treatment. The antiretroviral drug combination activated the pERK 
pathway and increased TNF-α levels in hippocampal tissue, independent of Tat infusion. 
Discussion: Our findings showed that antiretroviral drugs reversed Tat-induced formation of 
cleaved caspase-3, reducing apoptosis but did not reverse Tat-induced increase in lipid 
peroxidation and the synaptic marker, synaptophysin. The evidence suggests that the 
combination of antiretroviral drugs may be toxic, elevating hippocampal pERK and TNF-α 
levels. However, these effects could also be beneficial to the individual, since TNF-α has been 
shown to inhibit viral replication. The present results provide novel insight into the mechanism 
of antiretroviral action.  





Despite significant advances, the current number of people living with HIV has been 
estimated to be a staggering 35.3 million (UNAIDS report, 2013). Development of 
neurocognitive disorders in many HIV-infected individuals (Nakku et al., 2013) has added 
another dimension to the complexity of HIV/AIDS, and not withstanding extensive research, 
many questions regarding its pathophysiology and treatment remain unanswered. 
HIV-associated neurocognitive disorder (HAND) is a neurodegenerative disorder that is 
characterized by cognitive deficit and behavioral dysfunction. Brain autopsies performed on 
people who were HIV positive, showed that 90% of these individuals had severe neuron 
damage (Joska et al., 2011b). The HIV-1-trans-activating protein (Tat) has been strongly 
linked to the neuropathology observed in HAND patients (Bagashev and Sawaya, 2013). Tat 
is synthesized early after HIV infection and is responsible for viral replication (Sierra et al., 
2005). HIV rarely infects neuronal cells, but other brain cells such as macrophages and 
microglia, are infected by the virus (Wiley et al., 1986). These infected macrophages and 
microglia produce and shed Tat into the intercellular space from where it can exert its toxic 
effects (Williams et al., 2012). 
 Tat has been shown to be transported along anatomical pathways to reach subcortical areas 
such as the hippocampus, basal ganglia and striatum - brain regions that are important in 
cognitive function (McArthur et al., 2010). Tat employs a number of strategies to induce 
neuron damage. These include the activation of glutamate receptors (Dou et al., 2004), 
calcium overload (Agrawal et al., 2012), oxidative stress (Potter et al., 2013), apoptosis 
(Capone et al., 2013; Ramataur et al., 2012) and the release of pro-inflammatory cytokines 
(Williams et al., 2012). 
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The introduction of highly active antiretroviral therapy (HAART) which is aimed at targeting 
HIV at various stages of its life cycle, has effectively suppressed viral replication and 
partially restored immune function in humans (Ellis, 2010).  HAART has also reduced the 
prevalence of HAND from 50% to 20% (Manji et al., 2013). However, people living with 
HIV/AIDS are exposed to antiretroviral agents (ARVs) for long periods of time. The effects 
of long-term exposure to HAART have therefore been a major concern for clinicians and 
scientists worldwide. There is some evidence to suggest the drugs used in HAART cause 
metabolic disorder, lipodystrophy and diabetes (Leow et al., 2003, Waters and Nelson, 2007). 
Similarly nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase 
inhibitors have been suggested to induce mitochondrial dysfunction through the inhibition of 
DNA polymerase-gamma, resulting in increased production of ROS, causing oxidative 
damage and eventual organ malfunction (Lim and Copeland, 2001, Opii et al., 2007). With 
respect to brain function, there is controversy as to whether HAART helps to restore 
cognitive function in people living with HIV/AIDS (Cohen et al., 2001, Obiabo et al., 2012) 
or if antiretroviral agents in fact worsen cognitive decline (Giunta et al., 2011, Tovar-y-Romo 
et al., 2012). In support of the latter, a study by Robertson et al. (2010) showed that patients 
suffering from HAND who discontinue HAART, tend to regain their neuropsychological 
ability. Since the role of HAART in HIV-related neuropathogenesis appears to be unclear, 
our study subsequently investigated the impact of a currently used regime of ARVs on 







Materials and methods 
Animals 
Male Sprague-Dawley rats (250 g - 300 g) were obtained from the Biomedical Research 
Center at the University of KwaZulu-Natal. Animals were housed under standard laboratory 
conditions of a 12-hour light-dark cycle (lights on at 06:00), 25 
o
C room temperature, 
humidity of 70%, with free access to food and water. The University of KwaZulu-Natal 
Ethics Committee approved all experimental procedures and care of animals was in 
accordance with Institutional guidelines.  
Reagents  
Biologically active recombinant HIV-1 clade B Tat (1-86 amino acids) was purchased from 
Diatheva (Milan, Italy). Rabbit polyclonal phosphor-p44/42 MAPK (ERK1/2) 
(Thr202/Tyr204) antibody and β-Actin Rabbit monoclonal antibody were purchased from 
Cell Signaling Technology (USA). Rabbit polyclonal cleaved-Caspase-3, Active antibody, 
Mouse monoclonal anti-synaptophysin antibody and Rat Tumor Necrosis Factor-α (TNF-α) 
ELISA Kit were purchased from Sigma (St Louis, USA). The OxiSelect HNE Adduct 
Competitive ELISA Kit was purchased from Bio Cell (USA) and antiretroviral tablets 
Zidovudine (,1-[(2R,4S,5S)-4-Azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-
2,4-dione)Lamivudine (2′,3′-dideoxy-3′-thiacytidine) and Efavirenz (4S)-6-chloro-4-(2-
cyclopropylethynyl)-4-(trifluoromethyl)-2,4-dihydro-1H-3,1-benzoxazin-2-one)were 






Treatment of animals 
HIV-Tat was reconstituted in phosphate-buffered saline at 5 µg/10 µl concentration just prior 
to administration. Zidovudine, Lamivudine and Efavirenz were dissolved under sterile 
conditions in physiological saline and served as our highly active anti-retroviral therapy 
(HAART). The final doses of the respective drugs were 12 mg/kg Zidovudine, 6 mg/kg 
Lamivudine and 24 mg/kg Efavirenz and were similar to that presently prescribed to people 
living with HIV/AIDS in South Africa. 
Animals were divided into four groups (n=10 per group). Group 1 received bilateral 
intrahippocampal injections of saline (10 µl per injection) as well as an intraperitoneal 
injection of saline (1 ml/250 g). This group served as the control. Group 2 received bilateral 
intrahippocampal injections of Tat (5 μg per injection) dose was shown to cause 
neurodegeneration (Aksenov et al., 2001) and an intraperitoneal injection of saline. Group 3 
received intrahippocampal injections of Tat and an intraperitoneal injection of HAART (3 
mg/ml Zidovudine, 1.5 mg/ml Lamivudine, and 6 mg/ml Efavirenz). Group 4 received 
intrahippocampal injections of saline and an intraperitoneal injection of HAART. 
 
Stereotaxic surgery 
The animals were anaesthetized with sodium pentobarbital (60 mg/kg, intraperitoneally 
(i.p.)), then placed in a stereotaxic frame (David Kopf Instruments, Tujunga, USA). The skin 
covering the skull was removed to expose the calvarium. Bregma and lambda were used to 
level the horizontal plane of the skull. The stereotaxic rat atlas of Paxinos and Watson 5
th
 
Edition (2004) was used to obtain the coordinates to ensure that the injections were into the 
hippocampus. The following co-ordinates were adopted AP= -3.8 mm, ML= ± 2.6 mm and 
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DV= 3.2 mm. When the exact positions were located on the skull, small burr holes were 
drilled for the lowering of the injecting device into the brain. Tat protein (5 µg/10 µl) or 
saline (10 µl) were administered using a Hamilton syringe which had been pretreated with 
dimethyldichlorosilane to prevent the drug from adhering to the inner surface of the syringe. 
The injection rate was 1 µl/minute. The needle was left in place for a further 5 minutes to 
ensure optimal diffusion of the solution. Thereafter the needle was slowly retracted from the 
brain over a period of 1 minute. The hole in the skull was filled with sterile cellulose 
(Ethicon, UK) and the incision sutured, the wound disinfected with iodine solution and 
cellulose also used for the dressing of the wound (Purdue Frederic, USA). Animals were then 
placed on a heating blanket to prevent hypothermia. They were returned to their home cages 
after full recovery from surgery. 
After the intrahippocampal injections, animals were given 7 days to recover from surgery and 
for Tat neurotoxicity to manifest prior to HAART treatment. Previous studies in our 
laboratory have shown that toxic effects of HV-1 Tat is present on day 7 and this include 
abnormalities in learning and cognitive function (Makhathini et al., 2013). This was followed 
by a further 7 days treatment with either HAART or Saline. These treatments were given 
twice a day (10:00 and 16:00) intraperitoneally. At the end of the treatment, the animals were 
decapitated and their brains dissected. The hippocampal tissues were collected and snap 
frozen in liquid nitrogen and stored at -80 
o
C until biochemical analyses were performed, The 
tissue samples of different animals were used for each assay. 
Enzyme linked immunosorbent assay (ELISA) of 4-Hydroxynonenal (HNE) and Tumor 
necrosis factor α (TNF-α). 
4-Hydroxynonenal (HNE) production was quantified using a competitive ELISA. Plate wells 
were first coated with HNE conjugate after which 50 µl of sample supernatant or HNE 
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standards were added to each well and incubated for 10 minutes at room temperature. After 
brief incubation, 50 µl of anti-HNE antibody was added and incubated at room temperature 
for 1 hour on an orbital shaker. Secondary antibody-HRP conjugated (100 µl) was added to 
each well followed by addition of substrate solution for a color change reaction. 
TNF-α was quantified using a sandwich ELISA. Plate wells were pre-coated with rat TNF-α 
antibody. Sample supernatant or protein standard (100 µl) were added to each well and 
incubated for 2.5 hours at 4 
o
C with gentle shaking on an orbital shaker. Biotinylated anti-rat 
TNF-α antibody was added to each well. HRP-conjugated streptavidin was added to each 
well and incubated for 10 minutes followed by addition of (3, 3’, 5, 5’-tetramethylbenzidine) 
TMB substrate solution for color development and measurement of absorbance on a plate 
reader. 
Western blot analysis of caspase-3, synaptophysin and pERK1/2 
Hippocampal tissue was homogenized in 600 µl RIPA buffer (150 mM NaCl, 1000 mM Tris, 
10% SDS, Triton X 100, 24 mM Sodium deoxycholate and 500 mM EDTA). Homogenates 
were centrifuged twice at 3578 g for 10 minutes at 4 
o
C. Supernatant was collected and 
protein concentration determined using the Bradford method (Kruger, 2009). After protein 
determination and standardization of protein concentration, equal amount of protein samples 
(50 µg) were diluted with Bio Rad sample buffer (4% Sodium dodecyl sulfate, 20% Glycerol, 
125 mM Tris, 0.02% Bromophenol blue 200, 10% β-mercaptoethanol) in a ratio of 1:2. 
Samples were denatured for 5 minutes at 95 
o
C. Equal amounts of protein samples were 
resolved by electrophoresis on a 10% sodium dodecyl sulfate polyacrylamide gel (at 200 V 
for 1 hour) in running buffer (25 mM Tris base, 190 mM Glycine and 0.1% sodium dodecyl 
sulfate). Proteins were transferred onto nitrocellulose membrane (Bio-Rad) using transfer 
buffer (25 mM Tris base, 190 mM Glycine and 20% methanol) at 100 V for 1 hour. 
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Membrane was then blocked with 5% milk dissolved in 0.1% PBS-Tween (136.90 mM NaCl, 
2.68 mM KCl, 10.14 mM NaHPO4, 1.76 mM KH2PO4 0.1% Tween) for 2 hours before 
adding primary antibody (1:1000 dilution in TBS-Tween) and incubating overnight. The 
membrane was washed three times with 0.1 M PBS-Tween for 10 minutes. The secondary 
antibody (1:10000 dilutions) was added and incubated with membrane for 2 hours at room 
temperature. The membrane was then washed three times with PBS-Tween and washed once 
with PBS. Chemilunescence peroxidase substrate-3 reagents were added to the membrane 
and the membrane was viewed on a chemi-doc system (Bio-Rad, SA). Densitometric values 
were normalized to β-actin. 
Statistical analysis 
The data were analyzed using GraphPad Prism (version 5, San Diego, California, USA) and 
are expressed as mean ± SEM. The data were subjected to one-way analysis of variance 
(ANOVA) followed by Tukey’s post-hoc multiple comparison tests. Differences were 












 Cleaved -Caspase-3 levels in the hippocampal tissue 
Results of the ANOVA showed that there was a significant difference in cleaved caspase-3 
levels between the different groups [F(3, 15)=19.76,  p< 0.0001]. Tukey’s post-hoc test revealed 
that Tat+Saline and Saline+HAART treatment caused a significant increase in cleaved 
caspase-3 when compare to the Saline+Saline and Tat+HAART treated groups (p < 0.05, Fig. 
1b).   
Lipid peroxidation through quantification of 4-hydroxynonenal (HNE) in hippocampal 
tissue 
Results of the ANOVA showed that there was a significant difference in hippocampal HNE 
levels between the groups [F(3, 15)= 11.23, p< 0.0001]. Tukey’s post hoc test revealed that 
HNE levels were increased in all Tat and/or HAART treated groups when compared to the 
Saline+Saline group (p < 0.05, Fig. 2). 
TNF-α expression after Tat and HAART treatment 
 ANOVA revealed a significant difference in hippocampal TNF-α levels [F(3, 15)= 11.94,   p< 
0.0001]. Tukey’s post hoc test showed that Tat+HAART and Saline+HAART treated animals 
had a significantly higher level of TNF-α when they were compared to the Saline+Saline 
group of animals Figure 3. The TNF-α level in the Tat+HAART group of rats was 






Activation of extracellular signal-regulated kinase (pERK 1/2) pathway 
Results of the ANOVA showed that pERK levels differed significantly between groups [F(3, 
15)=13.91, p< 0.0001]. Tukey’s post hoc test revealed that Tat+HAART and Saline+HAART 
treated animals showed a significant increase in pERK1/2 protein levels when they were 
compared to the Saline+Saline group  (P < 0.05, Figure 4). Saline+HAART treatment caused 
a significant increase in pERK 1/2 when it was also compared to the Tat+Saline treated group 
(P < 0.05, Fig. 4b).                                
Synaptophysin expression after Tat and HAART treatment 
ANOVA revealed a significant difference in synaptophysin levels of the different groups [F(3, 
15)=4.200, p< 0.01]. Tukey’s post-host test showed that Tat+Saline and Tat+HAART caused a 
significant loss of Synaptophysin when they were compared to the Saline+Saline treated 













Our results show that Tat protein caused an increase in cleaved caspase-3 in rat hippocampal 
tissue. This concurs with previous studies which demonstrated that Tat increased cleaved 
caspase-3 in cell culture (Ramautar et al., 2012). Tat was suggested to induce an increase in 
cytoplasmic free Ca
2+
 concentration in rat hippocampal cell culture which activated gene 
transcription, leading to an increase in cleaved caspase-3 expression (Kruman et al., 1998). 
HAART treatment reduced the Tat-induced increase in cleaved caspase-3 protein expression 
in the rat hippocampus. This effect of HAART has not been shown before and the mechanism 
involved in this HAART effect is not known.  
Animals that received HAART treatment after saline injection into the hippocampus had a 
high expression of cleaved caspase-3 in the hippocampus. Previous studies have shown that 
at least one of the antiretroviral drugs used in the present study, Efavirenz cause apoptosis of 
neurons through cleave caspase-3 formation   (Opii et al., 2007, Bumpus, 2011). Treatment 
with HAART could therefore be detrimental.  
An increase of ROS in cells causes oxidative stress which leads to lipid peroxidation and 
other cell injuries (Berlett and Stadtman, 1997). One of the by-products of lipid peroxidation 
is HNE (Williams et al., 2006). Our results show that Tat caused an increase in HNE. This 
finding concurs with previous studies.   Pocernich et al. (2005) showed that Tat increased 
HNE in rat cerebral cortical neurons. Tat protein likely caused ROS production leading to 
increased lipid peroxidation and increased HNE (Haughey et al., 2004, Banerjee et al., 2010). 
Treatment with HAART did not reduce the Tat-induced increase in HNE levels. Animals that 
received only HAART also had high levels of HNE. This can be attributed to the fact that 
both nucleoside and non-nucleoside reverse transcriptase inhibitors have also been shown to 
cause accumulation of ROS in primary cortical neuroglia, pure neurons and astrocytes 
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isolated from embryonic Spague-Dawley rats (Akay et al., 2014).  Nucleoside and non-
nucleoside reverse transcriptase inhibitors inhibit mitochondrial DNA polymerase-gamma 
leading to impairment of mitochondrial DNA replication (Lim and Copeland, 2001). 
Depletion of mitochondrial DNA results in depletion of enzymes required for oxidative 
phosphorylation of ADP, hence ROS accumulation (Lim and Copeland, 2001, Akay et al., 
2014).  
HAART treatment increased TNF-α levels in both saline- and Tat-injected rat hippocampus 
while Tat had no effect. Since TNF-α has been shown to have anti-apoptotic effects through 
activation of NF-Ƙβ which increases expression of anti-apoptotic factors (Tamatani et al., 
1999), this may be the mechanism of its beneficial effects. 
Similarly, HAART treatment increased pERK levels in both the hippocampi of saline- and 
Tat-injected rats. The mechanism that leads to the increase of pERK is not known, but we 
suggest that it may be linked to the increase in TNF-α. Pulliam et al. (2001) showed that 
TNF-α increased pERK protein expression in brain cell cultures.   TNF-α has been shown to 
exert neuroprotective effects by activation of anti-apoptotic factors (Bcl-2 and Bcl-x) in rat 
primary hippocampal neurons (Tamatani et al., 1999). A study conducted by Seo and 
Webster (2002) showed that TNF-α inhibits influenza viral replication in cultured porcine 
lung epithelial cells. TNF-α has also been shown to inhibit HIV entry by down regulating 
CD4 expression in tissue culture-differentiated macrophages (Herbein et al., 1996).  HAART 
induced TNF-α production could be an additional benefitial effect of HAART, since TNF-α 
has anti-apoptotic and anti-viral replication effects. The absence of effect of Tat on TNF-α 
and pERK levels is contrary to expectation (Leghmari et al., 2008, Lee et al., 2011). This 
could be due to the fact that Tat stimulation of TNF-α expression is time-dependent and its 
effect may decrease over time (Leghmari et al., 2008). In this study the effects induced by Tat 
protein were observed after 14 days.  The study conducted by Agrawal et al. (2007) showed 
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that Tat induced apoptosis in primary neuron cultures in a dose- and time-dependent manner. 
Other studies showed that the initial effect of Tat such as astrocyte activation and oxidative 
stress are observed on day 7 after intracerebral injection of Tat (Bansal et al., 2000, Aksenov 
et al., 2003). Some of the effects of HAART on the brain may also result indirectly from its 
effects on peripheral tissue. For instance previous studies have shown that HAART increases 
in mRNA expression of IL-6 and TNF-α in adipose tissue (Lagathu et al., 2004). It is 
therefore possible that these proinflammatory cytokines can be produced peripherally, cross 
the BBB and mediate drug-induced negative effects on the brain. 
 
As shown in previous studies, Tat caused a loss of synaptophysin, consistent with a loss of 
presynaptic terminals in hippocampal neurons in culture  (Shin and Thayer, 2013). Treatment 
with HAART did not reverse synaptophysin loss, suggesting that it was unable to rescue 
synaptosomal loss.   
In conclusion, HAART treatment does have beneficial effects but it cannot reverse some of 
the toxic effects of Tat protein such as lipid peroxidation and decrease in synapse density.  
Our findings affirm the need for supplementary treatment in addition to antiretroviral therapy 
in patients with HIV. Also this study provides novel insight into a possible mechanism of 
HAART action against some of the neurotoxic effects of HIV Tat protein.  
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Fig. 1 Active caspase-3 levels in hippocampal tissue of rats that received bilateral intrahippocampal injections 
of Tat or saline, followed by treatment with HAART or saline for 7 days, 14 days after Tat injection. a The 
western blot representation of cleaved caspase-3 and β-actin. b Graph representing the cleaved caspase-3 
measurements after normalization against β-actin. *Significantly different from Saline+Saline group. # 
































Fig. 2 HNE levels in hippocampal tissue of rats that received bilateral intrahippocampal injections of Tat or 
saline, followed by treatment with HAART or saline for 7 days, 14 days after Tat injection. * Significantly 



































Fig. 3 TNF-α levels in hippocampal tissue of rats that received bilateral intrahippocampal injections of Tat or 
saline, followed by treatment with HAART or saline for 7 days, 14 days after Tat injection. *Significantly 















Fig. 4 Phosphorylated ERK 1/2 levels in hippocampal tissue of rats that received bilateral intrahippocampal 
injections of Tat or saline, followed by treatment with HAART or saline for 7 days, 14 days after Tat injection. 
a Western blot representation of pERK. b Graph showing pERK measurements after normalization against β-




































Fig. 5 Synaptophysin levels in hippocampal tissue of rats that received bilateral intrahippocampal injections of 
Tat or saline, followed by treatment with HAART or saline for 7 days, 14days after Tat injection. a Western blot 
representation of synaptophysin. b Graph showing synaptophysin measurements after normalization against β-
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Chapter 3  
Conclusions and Future considerations 
 The introduction of highly active antiretroviral therapy (HAART) has contributed positively 
to the life expectancy of people living with HIV by adding an 11.3 years gain from 49.2 to 
60.5 years (Bor et al., 2013). But as patients with HIV live longer, complications associated 
with long-term HAART begin to emerge (Schambelan et al., 2002). Despite extensive 
research done on the pathophysiology of HIV, investigations into HAART have been limited. 
The present study was subsequently conducted to improve the current understanding of the 
effects of HAART in the central nervous system and to assess its efficacy in protecting the 
central nervous system against the toxic effects of HIV Tat protein.  
Our first aim was to confirm that Tat protein is neurotoxic and indeed leads to cell death. By 
injecting Tat protein directly into rat’s hippocampus, we could show evidence of oxidative 
stress, apoptosis and decreased synapse formations. These findings clearly demonstrated the 
toxic effects of Tat protein and indicated the mechanism by which Tat protein could cause 
cell death. For the second aim we determined the potential of HAART to protect against Tat 
protein toxicity, rats that received bilateral injections of Tat protein into their dorsal 
hippocampus, were subsequently treated with a clinically-relevant combination of 
antiretroviral drugs. In these experiments we could show that the antiretroviral treatment was 
only partially effective in reversing the toxic effects of HIV Tat. Our third aim was to 
investigate whether HAART has any toxic effects on the central nervous system. Our 
findings revealed that HAART activated signaling pathways and stimulated the release of 
pro-inflammatory cytokines. These observations suggested that HAART might be toxic on its 
own and therefore the administration of these drugs to patients should be done with caution.  
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In conclusion, the findings of our study did not support our hypothesis entirely in that 
HAART was unable to reverse the toxic effects of HIV Tat protein completely. The data 
showed that HAART may have some beneficial effect but it is not efficient in protecting 
hippocampal cells against Tat protein induced damage. Since our experiments also showed 
that HAART may have deleterious effects itself, and therefore patients on HAART should be 
monitored carefully for signs of abnormal function of their central nervous system.   
The present study focused on the effects of Tat and HAART on certain proteins in the 
hippocampus. While informative, the proteins served only as a window into the consequences 
of Tat and HAART exposure. A more comprehensive proteomic approach should be 
considered in future studies as this may provide a broader understanding of how Tat and 
HAART influence the proteome of the hippocampus. A further benefit of such an approach 
would be the possible identification of alternative targets for intervention. Another aspect 
worthy of further investigation is the period of HAART treatment. Since we only treated our 
animals for 7 days while humans are on HAART for much longer, it would be useful to 
investigate the effects of a much longer period of drug administration. Of particular interest 
would be the effects of long term HAART on the epigenome and transcriptome of brain areas 
associated with cognitive function. And finally the current study only measured biochemical 
parameters. Inclusion of cognitive behavioural assessments for animals treated with Tat and 
HAART may provide additional insights into the molecular mechanisms underlying the 
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